These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 21491416)

  • 1. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.
    Zou CF; Jia L; Jin H; Yao M; Zhao N; Huan J; Lu Z; Bast RC; Feng Y; Yu Y
    BMC Cancer; 2011 Jan; 11():22. PubMed ID: 21244707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
    Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
    Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
    Zuo X; Qin Y; Zhang X; Ning Q; Shao S; Luo M; Yuan N; Huang S; Zhao X
    Oncol Rep; 2014 May; 31(5):2358-64. PubMed ID: 24676336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells.
    Brodská B; Otevřelová P; Holoubek A
    Oxid Med Cell Longev; 2014; 2014():165303. PubMed ID: 25140197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
    PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells.
    Abou Najem S; Khawaja G; Hodroj MH; Babikian P; Rizk S
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.
    Susanto JM; Colvin EK; Pinese M; Chang DK; Pajic M; Mawson A; Caldon CE; Musgrove EA; Henshall SM; Sutherland RL; Biankin AV; Scarlett CJ
    Int J Oncol; 2015 May; 46(5):2223-30. PubMed ID: 25695794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
    Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
    Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro.
    Abou Najem S; Khawaja G; Hodroj MH; Rizk S
    Curr Mol Pharmacol; 2019; 12(4):281-300. PubMed ID: 30868973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer.
    Meng F; Sun G; Zhong M; Yu Y; Brewer MA
    Br J Cancer; 2013 Feb; 108(3):579-86. PubMed ID: 23370212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
    Qin Y; Zhao X; Fang Y
    Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Decitabine (5-aza-2'-deoxycytidine, 5-aza-CdR) in Comparison with Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) on DNMT1, DNMT3a and DNMT3b, HDAC 1-3, SOCS 1, SOCS 3, JAK2, and STAT3 Gene Expression in Hepatocellular Carcinoma HLE and LCL-PI 11 Cell Lines.
    Sanaei M; Kavoosi F; Pourahmadi M
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2089-2098. PubMed ID: 34319031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
    Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
    Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.